Literature DB >> 22651561

Validation study of urinary metabolites as potential biomarkers for prostate cancer detection.

Sanjeewa Gamagedara1, Anthony T Kaczmarek, Yongqing Jiang, Xiaoliang Cheng, Xiaoling Cheng, Maduka Rupasinghe, Yinfa Ma.   

Abstract

BACKGROUND: Urinary metabolomic profiles have recently drawn a lot of attention owing to a debate regarding their possible role as potential clinical markers for prostate cancer. In this study, levels of proline, kynurenine, uracil and glycerol-3-phosphate in 126 patients with genitourinary malignancies were analyzed using a validated method and compared with no evidence of malignancy.
RESULTS: The statistical results showed that these biomarkers cannot differentiate prostate cancer from no evidence of malignancy or from other related cancer types, such as bladder cancer. In addition, there was no significant difference in biomarker levels for T1 stages, T2 stages and Gleason scores <7, ≥7. From the correlation study, results showed/demonstrated that age or serum prostate-specific antigen levels do not influence these metabolite concentrations in urine. However, the strong correlation between these metabolites and urinary creatinine concentrations implies that their occurrence is mainly due to renal excretion.
CONCLUSION: This detailed study shows that the aforementioned urinary metabolites are not reliable biomarkers for prostate cancer detection or for differentiating the aggressiveness of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22651561     DOI: 10.4155/bio.12.92

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  8 in total

1.  Evaluation of statistical techniques to normalize mass spectrometry-based urinary metabolomics data.

Authors:  Tyler Cook; Yinfa Ma; Sanjeewa Gamagedara
Journal:  J Pharm Biomed Anal       Date:  2019-09-03       Impact factor: 3.935

Review 2.  Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis.

Authors:  Sabareeswaran Krishnan; Shruthi Kanthaje; Devasya Rekha Punchappady; M Mujeeburahiman; Chandrahas Koumar Ratnacaram
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-28       Impact factor: 4.553

Review 3.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

4.  The Role of Sarcosine, Uracil, and Kynurenic Acid Metabolism in Urine for Diagnosis and Progression Monitoring of Prostate Cancer.

Authors:  Georgios Gkotsos; Christina Virgiliou; Ioanna Lagoudaki; Chrysanthi Sardeli; Nikolaos Raikos; Georgios Theodoridis; Georgios Dimitriadis
Journal:  Metabolites       Date:  2017-02-23

5.  A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers.

Authors:  Ana Rita Lima; Joana Pinto; Carina Carvalho-Maia; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

6.  Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility.

Authors:  Beatriz Jiménez; Mei Ran Abellona U; Panagiotis Drymousis; Michael Kyriakides; Ashley K Clift; Daniel S K Liu; Eleanor Rees; Elaine Holmes; Jeremy K Nicholson; James M Kinross; Andrea Frilling
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

Review 7.  The present and future of prostate cancer urine biomarkers.

Authors:  Marina Rigau; Mireia Olivan; Marta Garcia; Tamara Sequeiros; Melania Montes; Eva Colás; Marta Llauradó; Jacques Planas; Inés de Torres; Juan Morote; Colin Cooper; Jaume Reventós; Jeremy Clark; Andreas Doll
Journal:  Int J Mol Sci       Date:  2013-06-17       Impact factor: 5.923

8.  Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors.

Authors:  Kyo Chul Koo; Dong Hoon Lee; Seung Hwan Lee; Byung Ha Chung
Journal:  Prostate Int       Date:  2013-09-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.